BiotechTube

solifenacin succinate + mirabegron + mirabegron/solifenacin succinate

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phase 1

Conditions

Phase 1, Bioavailability, Healthy Subjects

Trial Timeline

Sep 1, 2012 → Nov 1, 2012

NCT ID
NCT02010944

About solifenacin succinate + mirabegron + mirabegron/solifenacin succinate

solifenacin succinate + mirabegron + mirabegron/solifenacin succinate is a phase 1 stage product being developed by Astellas Pharma for Phase 1. The current trial status is completed. This product is registered under clinical trial identifier NCT02010944. Target conditions include Phase 1, Bioavailability, Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02010944Phase 1Completed

Competing Products

20 competing products in Phase 1

See all competitors
ProductCompanyStageHype Score
TERN-701Terns PharmaceuticalsPhase 1/2
38
Tamsulosin HCl + Solifenacin Succinate + EC905Astellas PharmaPhase 1
33
Graceptor®Astellas PharmaPre-clinical
23
Lemborexant + PlaceboEisaiApproved
85
BIW-8962Kyowa KirinPhase 1/2
41
AcalabrutinibAstraZenecaPhase 1/2
41
Sacituzumab tirumotecanMerckPhase 2
52
progesterone + ProgesteroneMerckApproved
85
AsciminibNovartisPre-clinical
23
NilotinibNovartisPhase 3
77
Imatinib mesylateNovartisPhase 3
77
Imatinib Mesylate 600 MG Oral Tablet + Imatinib Mesylate 400 MG Oral Tablet + Imatinib MesylateNovartisPhase 3
77
ribociclib + TrametinibNovartisPhase 1
33
NilotinibNovartisApproved
85
ImatinibNovartisPhase 3
77
NilotinibNovartisApproved
85
GleevecNovartisPhase 2
52
Nilotinib + RuxolitinibNovartisPhase 1/2
41
ABL001NovartisPhase 3
77
asciminibNovartisPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85